Gene therapy involves identifying a gene of interest and then manipulating the expression of this gene through a variety of techniques. Here we specifically address gene therapy's role in cancer research. This paper will encompass thoroughly investigated techniques such as cancer vaccines and suicide gene therapy and the latest advancements in and applications of these techniques. It will also cover newer techniques such as Antisense Oligonucleotides and small interfering RNAs and how these technologies are being developed and used. The use of gene therapy continues to expand in cancer research and has an integral role in the advancement of cancer treatment.
References
1.
Hacein-Bey-AbinaS.Le DeistF.CarlierF.BouneaudC.HueC.De VillartayJ. P.ThrasherA. J.WulffraatN.SorensenR.Dupuis-GirodS.FischerA.DaviesE. G.KuisW.LeivaL.Cavazzana-CalvoM.Sustained Correction of X-linked Severe Combined Immunodeficiency by Ex Vivo Gene Therapy. N. Engl. J. Med.346, 1185–1193 (2002).
2.
Hacein-Bey-AbinaS.Von KalleC.SchmidtM.McCormackM. P.WulffraatN.LeboulchP.LimA.OsborneC. S.PawliukR.MorillonE.SorensenR.ForsterA.FraserP.CohenJ. I.de Saint BasileG.AlexanderI.WintergerstU.FrebourgT.AuriasA.Stoppa-LyonnetD.RomanaS.Radford-WeissI.GrossF.ValensiF.DelabesseE.MacintyreE.SigauxF.SoulierJ.LeivaL. E.WisslerM.PrinzC.RabbittsT. H.Le DeistF.FischerA.Cavazzana-CalvoM.LMO2-associated Clonal T Cell Proliferation in Two Patients After Gene Therapy for SCID-X1. Science302, 415–419 (2003).
SchulerM.HerrmannR.De GreveJ. L.StewartA. K.GatzemeierU.StewartD. J.LaufmanL.GrallaR.KuballJ.BuhlR.HeusselC. P.KommossF.PerruchoudA. P.ShepherdF. A.FritzM. A.HorowitzJ. A.HuberC.RochlitzC.Adenovirus-mediated Wild-type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-small-cell Lung Cancer: Results of a Multicenter Phase II Study. J. Clin. Oncol.19, 1750–1758 (2001).
5.
HarveyB. G.LeopoldP. L.HackettN. R.GrassoT. M.WilliamsP. M.TuckerA. L.KanerR. J.FerrisB.GondaI.SweeneyT. D.RamalingamR.KovesdiI.ShakS.CrystalR. G.Airway Epithelial CFTR mRNA Expression In Cystic Fibrosis Patients After Repetitive Administration of a Recombinant Adenovirus. J. Clin. Invest.104, 1245–1255 (1999).
6.
StolbergS. G.The Biotech Death of Jesse Gelsinger. NY Times Mag.136–140, 149–150 (1999).
7.
SmithL.ByersJ. F.Gene Therapy in the Post-Gelsinger Era. JONAS Healthc Law Ethics Regul.4, 104–110 (2002).
SturtzF. G.WaddellK.ShulokJ.ChenX.CarusoM.SansonM.SnodgrassH. R.PlatikaD.Variable Efficiency of the Thymidine Kinase/ Ganciclovir System in Human Glioblastoma Cell Lines: Implications for Gene Therapy. Hum. Gene Ther.8, 1945–1953 (1997).
10.
MullenC. A.CoaleM. M.LoweR.BlaeseR. M.Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated In Vivo with 5-fluorocytosine and Induce Protective Immunity to Wild Type Tumor. Cancer Res.54, 1503–1506 (1994).
11.
AswaqM.RichardsV.McFaddenS.Immunologic Response to Autologous Cancer Vaccine. Arch. Surg.89, 485–487 (1964).
12.
HegeK. M.CarboneD. P.Lung Cancer Vaccines and Gene Therapy. Lung Cancer 41 Suppl1, S103–113 (2003).
13.
ImS. S.MonkB. J.VillarrealL. P.Prevention of Cervical Cancer with Vaccines. Curr. Oncol. Rep.3, 322–328 (2001).
14.
LowyD. R.SchillerJ. T.Papillomaviruses and Cervical Cancer: Pathogenesis and Vaccine Development. J. Natl. Cancer Inst. Monogr.27–30 (1998).
15.
GissmannL.OsenW.MullerM.JochmusI.Therapeutic Vaccines for Human Papilloma-viruses. Intervirology44, 167–175 (2001).
16.
HerseyP.MenziesS. W.HallidayG. M.NguyenT.FarrellyM. L.DeSilvaC.LettM.Phase I/II Study of Treatment with Dendritic Cell Vaccines in Patients with Disseminated Melanoma. Cancer Immunol. Immunother.53, 125–134 (2004).
17.
TagawaS. T.LeeP.SnivelyJ.BoswellW.OunpraseuthS.LeeS.HickingbottomB.SmithJ.JohnsonD.WeberJ. S.Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma. Cancer9, 144–154 (2003).
18.
PantuckA. J.van OphovenA.GitlitzB. J.TsoC. L.AcresB.SquibanP.RossM. E.BelldegrunA. S.FiglinR. A.Phase I Trial of Antigen-specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-positive Patients with Advanced Prostate Cancer. J. Immunother.27, 240–253 (2004).
19.
DranoffG.JaffeeE.LazenbyA.GolumbekP.LevitskyH.BroseK.JacksonV.HamadaH.PardollD.MulliganR. C.Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-macrophage Colony-stimulating Factor Stimulates Potent, Specific, and Long-lasting Anti-tumor Immunity. Proc. Natl. Acad. Sci. USA90, 3539–3543 (1993).
20.
SoifferR.LynchT.MihmM.JungK.RhudaC.SchmollingerJ.C.HodiF. S.LiebsterL.LamP.MentzerS.SingerS.TanabeK. K.CosimiA. B.DudaR.SoberA.BhanA.DaleyJ.NeubergD.ParryG.RokovichJ.RichardsL.DrayerJ.BernsA.CliftS.DranoffG.Vaccination With Irradiated Autologous Melanoma Cells Engineered to Secrete Human Granulocyte-macrophage Colony-stimulating Factor Generates Potent Antitumor Immunity in Patients With Metastatic Melanoma. Proc. Natl. Acad. Sci. USA .95, 13141–13146 (1998).
21.
SimonsJ. W.JaffeeE. M.WeberC. E.LevitskyH. I.NelsonW. G.CarducciM. A.LazenbyA. J.CohenL. K.FinnC. C.CliftS. M.HaudaK. M.BeckL. A.LeifermanK. M.OwensA. H.Jr.PiantadosiS.DranoffG.MulliganR. C.PardollD. M.MarshallF. F.Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-macrophage Colony-stimulating Factor Gene Transfer. Cancer Res.57, 1537–1546 (1997).
22.
SimonsJ. W.MikhakB.ChangJ. F.DeMarzoA. M.CarducciM. A.LimM.WeberC. E.BaccalaA. A.GoemannM. A.CliftS. M.AndoD. G.LevitskyH. I.CohenL. K.SandaM. G.MulliganR. C.PartinA. W.CarterH. B.PiantadosiS.MarshallF. F.NelsonW. G.Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination With Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-macrophage Colony-stimulating Factor Using Ex Vivo Gene Transfer. Cancer Res.59, 5160–5168 (1999).
23.
SalgiaR.LynchT.SkarinA.LuccaJ.LynchC.JungK.HodiF. S.JaklitschM.MentzerS.SwansonS.LukanichJ.BuenoR.WainJ.MathisenD.WrightC.FidiasP.DonahueD.CliftS.HardyS.NeubergD.MulliganR.WebbI.SugarbakerD.MihmM.DranoffG.Vaccination with Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-macrophage Colony-stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-small-cell Lung Carcinoma. J. Clin. Oncol.21, 624–630 (2003).
24.
JaffeeE. M.HrubanR. H.BiedrzyckiB.LaheruD.SchepersK.SauterP. R.GoemannM.ColemanJ.GrochowL.DonehowerR. C.LillemoeK. D.O'ReillyS.AbramsR. A.PardollD. M.CameronJ. L.YeoC. J.Novel Allogeneic Granulocyte-macrophage Colony-stimulating Factor-secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. J. Clin. Oncol.19, 145–156 (2001).
25.
DudleyM. E.WunderlichJ. R.RobbinsP. F.YangJ. C.HwuP.SchwartzentruberD. J.TopalianS. L.SherryR.RestifoN. P.HubickiA. M.RobinsonM. R.RaffeldM.DurayP.SeippC. A.Rogers-FreezerL.MortonK. E.MavroukakisS. A.WhiteD. E.RosenbergS. A.Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science298, 850–854 (2002).
26.
NguyenD. M.SpitzF. R.YenN.CristianoR. J.RothJ. A.Gene Therapy for Lung Cancer: Enhancement of Tumor Suppression by a Combination of Sequential Systemic Cisplatin and Adenovirus-mediated p53 Gene Transfer. J. Thorac. Cardiovasc. Surg.112, 1372–1376; Discussion 1376–1377 (1996).
27.
KuballJ.WenS. F.LeissnerJ.AtkinsD.MeinhardtP.QuijanoE.EnglerH.HutchinsB.ManevalD.C.GraceM. J.FritzM. A.StorkelS. J.ThuroffW.HuberC.SchulerM.Successful Adenovirus-mediated Wild-type p53 Gene Transfer in Patients with Bladder Cancer by Intravesical Vector Instillation. J. Clin. Oncol.20, 957–965 (2002).
28.
PagliaroL. C.KeyhaniA.WilliamsD.WoodsD.LiuB.PerrotteP.SlatonJ. W.MerrittJ. A.GrossmanH. B.DinneyC. P.Repeated Intravesical Instillations of an Adenoviral Vector in Patients with Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy. J. Clin. Oncol.21, 2247–2253 (2003).
29.
LangF. F.BrunerJ. M.FullerG. N.AldapeK.PradosM.D.ChangS.BergerM. S.McDermottM. W.KunwarS. M.JunckL. R.ChandlerW.ZwiebelJ. A.KaplanR. S.YungW. K.Phase I Trial of Adenovirus-mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results. J. Clin. Oncol.21, 2508–2518 (2003).
30.
McNeishI. A.BellS. J.LemoineN.R.Gene Therapy Progress and Prospects: Cancer Gene Therapy Using Tumour Suppressor Genes. Gene Ther.11, 497–503 (2004).
31.
ZeimetA. G.MarthC.Why Did p53 Gene Therapy Fail in Ovarian Cancer?Lancet Oncol.4, 415–422 (2003).
32.
WolfB. B.SchulerM.LiW.Eggers-SedletB.LeeW.TailorP.FitzgeraldP.MillsG. B.GreenD. R.Defective Cytochrome C-dependent Caspase Activation in Ovarian Cancer Cell Lines Due to Diminished or Absent Apoptotic Protease Activating Factor-1 Activity. J. Biol. Chem.276, 34244–34251 (2001).
WildnerO.MorrisJ. C.The Role of the E1B 55 kDa Gene Product in Oncolytic Adenoviral Vectors Expressing Herpes Simplex Virus-tk: Assessment of Antitumor Efficacy and Toxicity. Cancer Res.60, 4167–4174 (2000).
35.
NemunaitisJ.CunninghamC.TongA. W.PostL.NettoG.PaulsonA. S.RichD.BlackburnA.SandsB.GibsonB.RandlevB.FreemanS.Pilot Trial of Intravenous Infusion of a Replication-selective Adenovirus (ONYX-015) in Combination with Chemotherapy or IL-2 Treatment in Refractory Cancer Patients. Cancer Gene Ther.10, 341–352 (2003).
36.
ReidT.GalanisE.AbbruzzeseJ.SzeD.AndrewsJ.RomelL.HatfieldM.RubinJ.KirnD.Intra-arterial Administration of a Replication-selective Adenovirus (dl1520) in Patients with Colorectal Carcinoma Metastatic to the Liver: A Phase I Trial. Gene Ther.8, 1618–1626 (2001).
37.
VaseyP. A.ShulmanL. N.CamposS.DavisJ.GoreM.JohnstonS.KirnD. H.O'NeillV.SiddiquiN.SeidenM.V.KayeS. B.Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-gene-deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients with Recurrent/ Refractory Epithelial Ovarian Cancer. J. Clin. Oncol.20, 1562–9 (2002).
38.
HechtJ. R.BedfordR.AbbruzzeseJ. L.LahotiS.ReidT. R.SoetiknoR. M.KirnD. H.FreemanS. M.A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clin. Cancer Res.9, 555–561 (2003).
39.
JounaidiY.WaxmanD. J.Use of Replication-conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-activation Genes for Cancer Therapy. Cancer Res.64, 292–303 (2004).
40.
RiesS. J.BrandtsC. H.ChungA. S.BiedererC. H.HannB. C.LipnerE. M.McCormickF.KornW. M.Loss of p14ARF in Tumor Cells Facilitates Replication of the Adenovirus Mutant dl1520 (ONYX-015). Nat. Med.6, 1128–1133 (2000).
41.
EdwardsS. J.DixB. R.MyersC. J.Dobson-LeD.HuschtschaL.HibmaM.RoydsJ.BraithwaiteA. W.Evidence that Replication of the Antitumor Adenovirus ONYX-015 is not Controlled by the p53 and p14(ARF) Tumor Suppressor Genes. J. Virol.76, 12483–12490 (2002).
42.
HaradaJ. N.BerkA. J.p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication. J. Virol.73, 5333–5344 (1999).
43.
ShenY.KitzesG.NyeJ. A.FattaeyA.HermistonT.Analyses of Single-amino-acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein. J. Virol.75, 4297–4307 (2001).
44.
JohnsonL.ShenA.BoyleL.KunichJ.PandeyK.LemmonM.HermistonT.GiedlinM.McCormickF.FattaeyA.Selectively Replicating Adenoviruses Targeting Deregulated E2F Activity are Potent, Systemic Antitumor Agents. Cancer Cell1, 325–337 (2002).
45.
LiD.DayK. V.YuS.ShiG.LiuS.GuoM.XuY.SreedharanS.O'MalleyB.W.Jr.The Role of Adenovirus-mediated Retinoblastoma 94 in the Treatment of Head and Neck Cancer. Cancer Res.62, 4637–4644 (2002).
46.
ZhangX.MultaniA. S.ZhouJ. H.ShayJ. W.McConkeyD.DongL.KimC. S.RosserC. J.PathakS.BenedictW. F.Adenoviral-mediated Retinoblastoma 94 Produces Rapid Telomere Erosion, Chromosomal Crisis, and Caspase-dependent Apoptosis in Bladder Cancer and Immortalized Human Urothelial Cells but Not in Normal Urothelial Cells. Cancer Res.63, 760–765 (2003).
47.
ChiuS. J.UenoN. T.LeeR. J.Tumor-targeted Gene Delivery Via Anti-HER2 Antibody (Trastuzumab, Herceptin2) Conjugated Polyethylenimine. J. Control Release9, 357–369 (2004).
48.
OehringR. D.MileticM.ValterM. M.PietschT.NeumannJ.FimmersR.SchlegelU.Vascular Endothelial Growth Factor (VEGF) in Astrocytic Gliomas — A Prognostic Factor? J. Neurooncol.45, 117–125 (1999).
49.
ValterM. M.HugelA.HuangH. J.CaveneeW. K.WiestlerO. D.PietschT.WernertN.Expression of the Ets-1 Transcription Factor in Human Astrocytomas is Associated with Fms-like Tyrosine Kinase-1 (Flt-1)/Vascular Endothelial Growth Factor Receptor-1 Synthesis and Neoangiogenesis. Cancer Res.59, 5608–5614 (1999).
50.
HuangH.ChevilleJ. C.PanY.RocheP. C.SchmidtL. J.TindallD. J.PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression. J. Biol. Chem.276, 38830–38836 (2001).
51.
TanakaM.GrossmanH. B.In Vivo Gene Therapy of Human Bladder Cancer with PTEN Suppresses Tumor Growth, Downregulates Phosphorylated Akt, and Increases Sensitivity to Doxorubicin. Gene Ther.10, 1636–1642 (2003).
52.
WaxmanD. J.SchwartzP.S.Harnessing Apoptosis for Improved Anticancer Gene Therapy. Cancer Res.63, 8563–8572 (2003).
53.
ChenL.WaxmanD. J.Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines Following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy. Cancer Res.55, 581–589 (1995).
54.
ChenL.YuL. J.WaxmanD. J.Potentiation of Cytochrome P450/Ccyclophosphamide-based Cancer Gene Therapy by Coexpression of the P450 Reductase Gene. Cancer Res.57, 4830–4837 (1997).
55.
WeiM. X.TamiyaT.ChaseM.BoviatsisE. J.ChangT. K.KowallN. W.HochbergF. H.WaxmanD.J.BreakefieldX. O.ChioccaE. A.Experimental Tumor Therapy in Mice Using the Cyclophosphamide-activating Cytochrome P450 2B1 Gene. Hum. Gene Ther.5, 969–978 (1994).
56.
BullerR. E.RunnebaumI. B.KarlanB. Y.HorowitzJ. A.ShahinM.BuekersT.PetrauskasS.KreienbergR.SlamonD.PegramM.A Phase I/II Trial of rAd/p53 (SCH 58500) Gene Replacement in Recurrent Ovarian Cancer. Cancer Gene Ther.9, 553–566 (2002).
57.
ChenG.WaxmanD. J.Role of Cellular Glutathione and Glutathione S-transferase in the Expression of Alkylating Agent Cytotoxicity in Human Breast Cancer Cells. Biochem. Pharmacol.47, 1079–1087 (1994).
58.
WaxmanD. J.Glutathione S-transferases: Role in Alkylating Agent Resistance and Possible Target for Modulation Chemotherapy — A Review. Cancer Res.50, 6449–6454 (1990).
59.
SladekN. E.Aldehyde Dehydrogenase-mediated Cellular Relative Insensitivity to the Oxazaphosphorines. Curr. Pharm. Des.5, 607–625 (1999).
60.
SchwartzP. S.ChenC. S.WaxmanD. J.Enhanced Bystander Cytotoxicity of P450 Gene-directed Enzyme Prodrug Therapy by Expression of the Antiapoptotic Factor p35. Cancer Res.62, 6928–6937 (2002).
61.
ClemR. J.MillerL. K.Control of Programmed Cell Death by the Baculovirus Genes p35 and iap. Mol. Cell. Biol.14, 5212–5222 (1994).
62.
AltieriD. C.Validating Survivin as a Cancer Therapeutic Target. Nat. Rev. Cancer3, 46–54 (2003).
63.
HerseyP.ZhangX. D.Overcoming Resistance of Cancer Cells to Apoptosis. J. Cell Physiol.196, 9–18 (2003).
64.
LockR. B.StribinskieneL.Dual Modes of Death Induced by Etoposide in Human Epithelial Tumor Cells Allow Bcl-2 to Inhibit Apoptosis Without Affecting Clonogenic Survival. Cancer Res.56, 4006–4012 (1996).
65.
YinD. X.SchimkeR. T.BCL-2 Expression Delays Drug-induced Apoptosis but Does Not Increase Clonogenic Survival After Drug Treatment in HeLa Cells. Cancer Res.55, 4922–4928 (1995).
66.
RoyN.DeverauxQ. L.TakahashiR.SalvesenG. S.ReedJ. C.The c-IAP-1 and c-IAP-2 Proteins are Direct Inhibitors of Specific Caspases. Embo J.16, 6914–6925 (1997).
67.
XueL.FletcherG. C.TolkovskyA.M.Mitochondria are Selectively Eliminated from Eukaryotic Cells after Blockade of Caspases During Apoptosis. Curr. Biol.11, 361–365 (2001).
68.
DeverauxQ. L.RoyN.StennickeH. R.Van ArsdaleT.ZhouQ.SrinivasulaS. M.AlnemriE. S.SalvesenG. S.ReedJ. C.IAPs Block Apoptotic Events Induced by Caspase-8 and Cytochrome c by Direct Inhibition of Distinct Caspases. Embo. J.17, 2215–2223 (1998).
69.
SheikhM. S.FornaceA. J.Jr.Death and Decoy Receptors and p53-mediated Apoptosis. Leukemia14, 1509–1513 (2000).
70.
BortulR.TazzariP. L.CappelliniA.TabelliniG.BilliA. M.BareggiR.ManzoliL.CoccoL.MartelliA. M.Constitutively Active Akt1 Protects HL60 Leukemia Cells from TRAIL-induced Apoptosis Through a Mechanism Involving NF-kappaB Activation and cFLIP(L) Up-regulation. Leukemia17, 379–389 (2003).
71.
KimS. H.KimJ. H.DjordjevicB.Effects of x-irradiation on RNA and Protein Synthesis in HeLa Cells. Radiat. Res.42, 577–589 (1970).
72.
HallahanD. E.VirudachalamS.BeckettM.ShermanM. L.KufeD.WeichselbaumR. R.Mechanisms of X-ray-mediated Protoonco-gene c-jun Expression in Radiation-induced Human Sarcoma Cell Lines. Int. J. Radiat. Oncol. Biol. Phys.21, 1677–1681 (1991).
73.
ChastelC.JiricnyJ.JaussiR.Activation of Stress-responsive Promoters by Ionizing Radiation for Deployment in Targeted Gene Therapy. DNA Repair (Amst)3, 201–215 (2004).
74.
BrachM. A.HassR.ShermanM. L.GunjiH.WeichselbaumR.KufeD.Ionizing Radiation Induces Expression and Binding Activity of the Nuclear Factor kappa B. J. Clin. Invest.88, 691–695 (1991).
75.
HallahanD. E.SukhatmeV.P.ShermanM.L.VirudachalamS.KufeD.WeichselbaumR. R.Protein Kinase C Mediates X-ray Inducibility of Nuclear Signal Transducers EGR1 and JUN. Proc. Natl. Acad. Sci. USA88, 2156–2160 (1991).
76.
HallahanD. E.VirudachalamS.ShermanM. L.HubermanE.KufeD. W.WeichselbaumR.R.Tumor Necrosis Factor Gene Expression is Mediated by Protein Kinase C Following Activation by Ionizing Radiation. Cancer Res.51, 4565–4569 (1991).
77.
WeichselbaumR. R.HallahanD. E.SukhatmeV. P.KufeD. W.Gene Therapy Targeted by Ionizing Radiation. Int. J. Radiat. Oncol. Biol. Phys.24, 565–567 (1992).
78.
HallahanD. E.BeckettM. A.KufeD.WeichselbaumR. R.The Interaction Brecombinant Human Tumor Necrosis Factor and Radiation in 13 Human Tumor Cell Lines. Int. J. Radiat. Oncol. Biol. Phys.19, 69–74 (1990).
79.
HallahanD. E.MauceriH. J.SeungL. P.DunphyE. J.WayneJ. D.HannaN. N.ToledanoA.HellmanS.KufeD. W.WeichselbaumR. R.Spatial and Temporal Control of Gene Therapy Using Ionizing Radiation. Nat. Med.1, 786–791 (1995).
80.
ChungT. D.MauceriH. J.HallahanD. E.YuJ. J.ChungS.GrdinaW. L.YajnikS.KufeD. W.WeichselbaumR. R.Tumor Necrosis Factor-alpha-based Gene Therapy Enhances Radiation Cytotoxicity in Human Prostate Cancer. Cancer Gene Ther.5, 344–349 (1998).
81.
MauceriH. J.SeetharamS.BeckettM. A.LeeJ. Y.GuptaV. K.GatelyS.StackM. S.BrownC. K.SwedbergK.KufeD. W.WeichselbaumR. R.Tumor Production of Angiostatin is Enhanced after Exposure to TNF-alpha. Int. J. Cancer97, 410–415 (2002).
82.
SenzerN.ManiS.RosemurgyA.NemunaitisJ.CunninghamC.GuhaC.BayolN.GillenM.ChuK.RasmussenC.RasmussenH.KufeD.WeichselbaumR.HannaN.TNFerade Biologic, An Adenovector with a Radiation-inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients with Solid Tumors. J. Clin. Oncol.22, 592–601 (2004).
83.
MarkertJ. M.MalickA.CoenD. M.MartuzaR. L.Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir. Neurosur-gery32, 597–603 (1993).
84.
ChouJ.RoizmanB.The Gamma 1(34.5) Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programed Cell Death in Neuronal Cells. Proc. Natl. Acad. Sci. USA89, 3266–3270 (1992).
85.
AdvaniS. J.SibleyG.S.SongP.Y.HallahanD.E.KataokaY.RoizmanB.WeichselbaumR. R.Enhancement of Replication of Genetically Engineered Herpes Simplex Viruses by Ionizing Radiation: A New Paradigm for Destruction of Therapeutically Intractable Tumors. Gene Ther.5, 160–165 (1998).
86.
SchoensiegelF.PaschenA.SiegerS.EskerskiH.MierW.RothfelsH.KleinschmidtJ.SchadendorfD.HaberkornU.MIA (Melanoma Inhibitory Activity) Promoter Mediated Tissue-specific Suicide Gene Therapy of Malignant Melanoma. Cancer Gene Ther.11, 408–418 (2004).
87.
TanJ.HallahanD.Growth Factor-independent Activation of Akt Contributes to the Viability of Irradiated Vascular Endothelium. Int. J. Radiat. Oncol. Biol. Phys.57 (2 Suppl), S316–317 (2003).
88.
TanJ.HallahanD. E.Growth Factor-independent Activation of Protein Kinase B Contributes to the Inherent Resistance of Vascular Endothelium to Radiation-induced Apoptotic Response. Cancer Res.63, 7663–7667 (2003).
89.
LuB.MuY.CaoC.ZengF.SchneiderS.TanJ.PriceJ.ChenJ.FreemanM.HallahanD. E.Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Cancer Res.64, 2840–2845 (2004).
90.
HeleneC.ToulmeJ. J.Specific Regulation of Gene Expression by Antisense, Sense and Antigene Nucleic Acids. Biochim. Biophys. Acta.1049, 99–125 (1990).
91.
PeymanA.HelsbergM.KretzschmarG.MagM.GrableyS.UhlmannE.Inhibition of Viral Growth by Antisense Oligonucleotides Directed Against the IE110 and the UL30 mRNA of Herpes Simplex Virus Type-1. Biol. Chem. Hoppe. Seyler.376, 195–198 (1995).
92.
SmithL.AndersenK. B.HovgaardL.JaroszewskiJ. W.Rational Selection of Antisense Oligonucleotide Sequences. Eur. J. Pharm. Sci.11, 191–198 (2000).
93.
CrookeS. T.Progress in Antisense Therapeutics. Hematol. Pathol.9, 59–72 (1995).
94.
ZhangZ.WangH.LiM.AgrawalS.ChenX.ZhangR.MDM2 is a Negative Regulator of p21WAF1/CIP1, Independent of p53. J. Biol. Chem.279, 16000–16006 (2004).
95.
WangH.NanL.YuD.AgrawalS.ZhangR.Antisense Anti-MDM2 Oligonucleotides as a Novel Therapeutic Approach to Human Breast Cancer: In Vitro and In Vivo Activities and Mechanisms. Clin. Cancer Res.7, 3613–3624 (2001).
96.
FreedmanD. A.LevineA. J.Regulation of the p53 Protein by the MDM2 Oncoprotein — Thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res.59, 1–7 (1999).
97.
MuZ.HachemP.AgrawalS.PollackA.Antisense MDM2 Sensitizes Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination. Int. J. Radiat. Oncol. Biol. Phys.58, 336–343 (2004).
98.
DillaT.RomeroJ.SanstistebanP.VelascoJ. A.The mdm2 Proto-oncogene Sensitizes Human Medullary Thyroid Carcinoma Cells to Ionizing Radiation. Oncogene21, 2376–2386 (2002).
KamiyamaM.IchikawaY.IshikawaT.ChishimaT.HasegawaS.HamaguchiY.NagashimaY.MiyagiY.MitsuhashiM.HyndmanD.HoffmanR. M.OhkiS.ShimadaH.VEGF Receptor Antisense Therapy Inhibits Angiogenesis and Peritoneal Dissemination of Human Gastric Cancer in Nude Mice. Cancer Gene Ther.9, 197–201 (2002).
101.
ShiY.Mechanisms of Caspase Activation and Inhibition During Apoptosis. Mol. Cell9, 459–470 (2002).
102.
ElbashirS. M.HarborthJ.LendeckelW.YalcinA.WeberK.TuschlT.Duplexes of 21-nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells. Nature411, 494–498 (2001).
103.
FireA.XuS.MontgomeryM. K.KostasS.A.DriverS. E.MelloC. C.Potent and Specific Genetic Interference by Double-stranded RNA in Caenorhabditis Elegans. Nature391, 806–811 (1998).
ZamoreP. D.Ancient Pathways Programmed by Small RNAs. Science296, 1265–1269 (2002).
108.
DykxhoornD. M.NovinaC.D.SharpP. A.Killing the Messenger: Short RNAs that Silence Gene Expression. Nat. Rev. Mol. Cell Biol.4, 457–467 (2003).
109.
KawasakiH.TairaK.Short Hairpin Type of dsRNAs That are Controlled by tRNA(Val) Promoter Significantly Induce RNAi-mediated Gene Silencing in the Cytoplasm of Human Cells. Nucleic Acids Res.31, 700–707 (2003).
110.
KawasakiH.TsunemiM.IyoM.OshimaK.MinoshimaH.HamadaA.OnukiR.SuyamaE.TairaK.A Functional Gene Discovery in Cell Differentiation by Hybrid Ribozyme and siRNA Libraries. Nucleic Acids Res. Suppl. 275–276 (2002).
111.
FutamiT.MiyagishiM.SekiM.TairaK.Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against bcl-2. Nucleic Acids Res. Suppl. 251–252 (2002).
112.
MiyagishiM.TairaK.Development and Application of siRNA expression Vector. Nucleic Acids Res. Suppl. 113–114 (2002).
113.
HamadaM.OhtsukaT.KawaidaR.KoizumiM.MoritaK.FurukawaH.ImanishiT.MiyagishiM.TairaK.Effects on RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev.12, 301–309 (2002).
114.
TakagiY.SuyamaE.KawasakiH.MiyagishiM.TairaK.Mechanism of Action of Hammerhead Ribozymes and Their Applications In Vivo: Rapid Identification of Functional Genes in the Post-genome Era by Novel Hybrid Ribozyme Libraries. Biochem. Soc. Trans.30, 1145–1149 (2002).
115.
MiyagishiM.TairaK.U6 Promoter-driven siRNAs with Four Uridine 3′Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells. Nat. Biotechnol.20, 497–500 (2002).
116.
AkashiH.MiyagishiM.TairaK.Suppression of Gene Expression by RNA Interference in Cultured Plant Cells. Antisense Nucleic. Acid Drug Dev.11, 359–367 (2001).
117.
TomarR. S.MattaH.ChaudharyP. M.Use of Adeno-associated Viral Vector for Delivery of Small Interfering RNA. Oncogene22, 5712–5715 (2003).
118.
MattaH.HozayevB.TomarR.ChughP.ChaudharyP. M.Use of Lentiviral Vectors for Delivery of Small Interfering RNA. Cancer Biol. Ther.2, 206–210 (2003).
119.
HagstromJ. E.HeggeJ.ZhangG.NobleM.BudkerV.LewisD. L.HerweijerH.WolffJ. A.A Facile Nonviral Method for Delivering Genes and siRNAs to Skeletal Muscle of Mammalian Limbs. Mol. Ther.10, 386–398 (2004).
120.
LewisD. L.HagstromJ. E.LoomisA. G.WolffJ. A.HerweijerH.Efficient Delivery of siRNA for Inhibition of Gene Expression in Postnatal Mice. Nat. Genet.32, 107–108 (2002).
121.
ChenJ.WallN. R.KocherK.DuclosN.FabbroD.NeubergD.GriffinJ. D.ShiY.GillilandD. G.Stable Expression of Small Interfering RNA Sensitizes TEL-PDGFbetaR to Inhibition with Imatinib or Rapamycin. J. Clin. Invest.113, 1784–1791 (2004).
122.
GuoJ.VermaU. N.GaynorR. B.FrenkelE. P.BecerraC. R.Enhanced Chemosensitivity to Irinotecan by RNA Interference-mediated Down-regulation of the Nuclear Factor-kappaB p65 Subunit. Clin. Cancer Res.10, 3333–3341 (2004).
PengY.ZhangQ.NagasawaH.OkayasuR.LiberH. L.BedfordJ. S.Silencing Expression of the Catalytic Subunit of DNA-dependent Protein Kinase by Small Interfering RNA Sensitizes Human Cells for Radiation-induced Chromosome Damage, Cell Killing, and Mutation. Cancer Res.62, 6400–6404 (2002).
125.
TakeiY.KadomatsuK.YuzawaY.MatsuoS.MuramatsuT.A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics. Cancer Res.64, 3365–3370 (2004).
126.
EdwardsE.GengL.TanJ.OnishkoH.DonnellyE.HallahanD. E.Phosphatidylinositol 3-kinase/Akt Signaling in the Response of Vascular Endothelium to Ionizing Radiation. Cancer Res.62, 4671–4677 (2002).
